Cargando…

MARC

LEADER 00000cam a2200000Ma 4500
001 EBOOKCENTRAL_ocn847649930
003 OCoLC
005 20240329122006.0
006 m o d
007 cr cn|||||||||
008 090330s2009 nyu ob 001 0 eng d
040 |a E7B  |b eng  |e pn  |c E7B  |d OCLCO  |d N$T  |d OCLCF  |d OCLCQ  |d OCLCO  |d YDXCP  |d OCLCQ  |d EBLCP  |d OCLCO  |d DEBSZ  |d OCLCQ  |d OCLCO  |d AZK  |d OCLCO  |d LOA  |d MOR  |d CCO  |d PIFAG  |d ZCU  |d MERUC  |d OCLCQ  |d U3W  |d STF  |d WRM  |d COCUF  |d NRAMU  |d ICG  |d VT2  |d OCLCO  |d WYU  |d OCLCQ  |d TKN  |d DKC  |d OCLCO  |d AU@  |d OCLCQ  |d OCLCO  |d OCLCQ  |d OCLCA  |d OCLCQ  |d OCLCA  |d OCLCO  |d OCL  |d OCLCQ  |d OCLCO  |d OCLCL 
019 |a 923657824  |a 961569319  |a 962707881 
020 |a 9781608767267  |q (electronic bk.) 
020 |a 1608767264  |q (electronic bk.) 
020 |z 1607415933  |q (hardcover ;  |q alk. paper) 
020 |z 9781607415930  |q (hardcover ;  |q alk. paper) 
029 1 |a AU@  |b 000053300415 
029 1 |a DEBBG  |b BV044087489 
029 1 |a DEBSZ  |b 449537552 
029 1 |a DEBSZ  |b 454916469 
029 1 |a NZ1  |b 15345586 
035 |a (OCoLC)847649930  |z (OCoLC)923657824  |z (OCoLC)961569319  |z (OCoLC)962707881 
050 4 |a RC280.B8  |b L2715 2009eb 
072 7 |a HEA  |x 039030  |2 bisacsh 
082 0 4 |a 362.196/99449  |2 22 
082 0 4 |a 362.196/99449  |2 23 
049 |a UAMI 
100 1 |a Lacroix, Marc,  |d 1963- 
245 1 0 |a Molecular therapy of breast cancer :  |b classicism meets modernity /  |c Marc Lacroix. 
260 |a New York :  |b Nova Biomedical Books,  |c ©2009. 
300 |a 1 online resource (viii, 291 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Cancer etiology, diagnosis and treatments series 
504 |a Includes bibliographical references and index. 
505 0 |a ""Molecular Therapy of Breast Cancer: Classicism Meets Modernity""; ""Dedication""; ""Contents ""; ""Preface""; ""Introduction ""; ""References ""; ""Selective Estrogen Receptor Modulators (SERMs) and Down-Regulators (SERDs)""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Selective Estrogen Receptor Modifiers (SERMs) ""; ""Tamoxifen ""; ""Toremifene ""; ""Fulvestrant ""; ""Conclusion ""; ""References ""; ""Aromatase Inhibitors ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Anastrozole ""; ""Letrozole ""; ""Exemestane "" 
505 8 |a ""Conclusion """"References ""; ""Agents Inducing Ovarian Suppression ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Goserelin ""; ""Triptorelin""; ""Leuprolide ""; ""Conclusion ""; ""References ""; ""Antimetabolites ""; ""Abstract ""; ""Introduction""; ""Clinical Trials in January 2009 ""; ""Fluorouracil ""; ""Capecitabine ""; ""Gemcitabine ""; ""Pemetrexed ""; ""Methotrexate ""; ""Conclusion ""; ""References""; ""Alkylating Agents ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Cyclophosphamide "" 
505 8 |a ""Platinum Compounds (Cisplatin, Carboplatin, Oxaliplatin, Picoplatin) -- Generalities """"Cisplatin ""; ""Carboplatin ""; ""Oxaliplatin ""; ""Picoplatin ""; ""Temozolomide ""; ""Thiotepa""; ""Ifosfamide ""; ""Melphalan ""; ""Busulfan ""; ""Conclusion ""; ""References ""; ""Anthracyclines ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Doxorubicin ""; ""Liposomal Doxorubicin ""; ""Epirubicin ""; ""Conclusion ""; ""References""; ""Microtubule-Binding Agents ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Taxanes -- Generalities "" 
505 8 |a ""Larotaxel """"Docetaxel ""; ""Paclitaxel and Nab-Paclitaxel ""; ""Epothilones -- Generalities ""; ""Ixabepilone ""; ""Patupilone ""; ""Sagopilone ""; ""Vinca Alkaloids -- Generalities ""; ""Vinorelbine""; ""Vinflunine ""; ""Eribulin ""; ""Conclusion ""; ""References ""; ""Topoisomerase Inhibitors ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Irinotecan ""; ""Etoposide ""; ""Conclusion ""; ""References""; ""HER Family Inhibitors ""; ""Abstract""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Trastuzumab ""; ""Lapatinib ""; ""Gefitinib "" 
505 8 |a ""Erlotinib """"Pertuzumab ""; ""Cetuximab ""; ""Ertumaxomab ""; ""Neratinib ""; ""Trastuzumab-MCC-DM1 ""; ""BIBW 2992 ""; ""ARRY-334543 ""; ""Conclusion ""; ""References ""; ""Angiogenesis Inhibitors ""; ""Abstract""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Bevacizumab""; ""Sunitinib ""; ""Vandetanib ""; ""Pazopanib ""; ""Ramucirumab ""; ""ABT-869 ""; ""AV-951 ""; ""PTC299""; ""AMG 386 ""; ""Aflibercept ""; ""Conclusion""; ""References ""; ""Insulin-Like Growth Factor-I Receptor (IGF-1R) Inhibitors""; ""Abstract""; ""Introduction ""; ""Clinical Trials in January 2009"" 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
650 0 |a Breast  |x Cancer  |x Molecular aspects. 
650 0 |a Antineoplastic agents. 
650 0 |a Antimitotic agents. 
650 1 2 |a Breast Neoplasms  |x drug therapy 
650 2 2 |a Antineoplastic Agents  |x therapeutic use 
650 2 2 |a Enzyme Inhibitors  |x therapeutic use 
650 2 |a Antineoplastic Agents 
650 2 |a Antimitotic Agents 
650 6 |a Sein  |x Cancer  |x Aspect moléculaire. 
650 6 |a Anticancéreux. 
650 7 |a HEALTH & FITNESS  |x Diseases  |x Cancer.  |2 bisacsh 
650 7 |a Antimitotic agents  |2 fast 
650 7 |a Antineoplastic agents  |2 fast 
650 7 |a Breast  |x Cancer  |x Molecular aspects  |2 fast 
758 |i has work:  |a Molecular therapy of breast cancer (Text)  |1 https://id.oclc.org/worldcat/entity/E39PCG9XwgDvmYBgTdpFMgH8cq  |4 https://id.oclc.org/worldcat/ontology/hasWork 
776 0 8 |i Print version:  |a Lacroix, Marc, 1963-  |t Molecular therapy of breast cancer.  |d New York : Nova Biomedical Books, ©2009  |w (DLC) 2009013524 
830 0 |a Cancer etiology, diagnosis, and treatments. 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=3018284  |z Texto completo 
938 |a ProQuest Ebook Central  |b EBLB  |n EBL3018284 
938 |a ebrary  |b EBRY  |n ebr10660145 
938 |a EBSCOhost  |b EBSC  |n 311198 
938 |a YBP Library Services  |b YANK  |n 10225855 
994 |a 92  |b IZTAP